Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327699 · ClinicalTrials.gov registry record · Early Phase 1
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
A Early Phase 1 study of Major Depressive Disorder, sponsored by Emory University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT05327699 is a Early Phase 1 study of Major Depressive Disorder that is actively recruiting participants, run by Emory University. The registered enrollment target is 140 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05327699, a Early Phase 1 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ketamine
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05327699
The ClinicalTrials.gov registry entry for NCT05327699 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (63% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05327699 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05327699 about?
NCT05327699 is a clinical study titled "Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine". The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
What is the current status of trial NCT05327699?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 140 participants. The study started on 2022-11-08. Estimated completion is 2026-12-31.
What conditions does trial NCT05327699 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05327699?
The interventions under investigation include: Placebo (OTHER), Ketamine (DRUG).
Who is sponsoring clinical trial NCT05327699?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05327699 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
-
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.